+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital

131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital

Cancer BioTherapy & Radiopharmaceuticals 18(4): 513-524

In order to increase the availability and affordability of radioimmunotherapy of refractory or relapsed non-Hodgkins lymphoma, we developed and evaluated radioiodinated rituximab in an ongoing physician-sponsored Phase II Clinical Trial. The chimeric 1gG(1) anti CD 20 monoclonal antibody rituximab was radiolabeled with iodine-131 using a modified Chloramine T method with high radiochemical purity (98% +/- 0.82) and preservation of immunoreactivity. All patients received therapeutic loading doses of unlabeled rituximab (375 mg/m(2)) immediately prior to administration of tracer (200 MBq (131)I) or therapy (1.7-4.3 GBq (131)I) activities of (131)I-rituximab to provide additive immunotherapy and enhance tumor uptake of the radiolabeled antibody. Objective response rate (ORR) was 71% in 35 patients with a median follow-up of 14 months (range 4-28 months). Complete remission (CR) was achieved in 54% of patients, with median duration 20 months. Toxicity evaluation included an additional 7 patients followed for at least 3 months. Tracer dosimetry studies were performed in each patient and the whole body radiation absorbed dose was limited to a mean prescribed dose (MPD) of 0.75 Gy. Myelosuppression was reversible and in only 2 of 42 patients was grade IV hematological toxicity observed. No hemopoietic support was required in any patient. There was no instance of hemorrhage or infection in this group of patients in each of whom individual prospective dosimetry was performed prior to (131)I rituximab radioimmunotherapy for relapsed or refractory non-Hodgkins lymphoma.

(PDF emailed within 0-6 h: $19.90)

Accession: 010039307

Download citation: RISBibTeXText

PMID: 14503945

DOI: 10.1089/108497803322287583

Related references

Radioimmunotherapy with 131I anti-CD20 chimeric monoclonal antibody for relapsed or refractory non-Hodgkins lymphoma. Journal of Nuclear Medicine 43(5 Supplement): 115P-116P, 2002

Human-mouse chimeric 131I-labeled anti-CD20 monoclonal antibody in relapsed non-Hodgkins lymphoma Dosimetry and radioimmunotherapy. Journal of Nuclear Medicine 41(5 Suppl ): 268P, 2000

Tandem HD-chemotherapy and myeloablative radioimmunotherapy with 131I-anti-CD20 rituximab in relapsed and refractory B-cell lymphoma: Results of a phase II study of the German RAIT Study Group. Journal of Clinical Oncology 24(18_suppl): 13007-13007, 2016

High dose 131I anti - CD20 radioimmunotherapy for relapsed or refractory mantle cell lymphoma Radiation absorbed dose evaluation. Journal of Nuclear Medicine 42(5 Supplement): 157P, 2001

IDEC-Y2B8 90yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkins lymphoma Interim results of a phase I/II trial. Blood 90(10 SUPPL 1 PART 1): 586A, Nov 15, 1997

High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. Journal of Clinical Oncology 25(11): 1396-1402, 2007

Phase-II Trial of Rituximab in Patients with Relapsed CD20-Positive Hodgkins Lymphoma An Update from the German Hodgkins Lymphoma Study Group. Blood 100(11): Abstract No 3066, November 16, 2002

Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue. Annals of Hematology 90(11): 1307-1315, 2011

High-dose, myeloablative radioimmunotherapy of mantle cell non-Hodgkins lymphoma with the 131I-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support Results of a pilot study. Cancer Biotherapy & Radiopharmaceuticals 15(4): 408, 2000

Chimeric anti-CD20 monoclonal antibody (rituximab; mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Final analysis of a phase III randomized intergroup clinical trial. 2006

Tandem myeloablative 131I-rituximab radioimmunotherapy and high-dose chemotherapy in refractory/relapsed non-Hodgkin lymphoma patients. ImmunoTherapy 5(12): 1283-1286, 2014

A phase II trial of CHOP followed by rituximab chimeric monoclonal anti-CD20 antibody for treatment of newly diagnosed follicular non-Hodgkins lymphoma SWOG 9800. Blood 98(11 Part 1): 843a, November 16, 2001

Reduced-dose ZevalinTM radioimmunotherapy for relapsed or refractory B-cell non-Hodgkins lymphoma patients with pre-existing thrombocytopenia Report of interim results of a phase II trial. Blood 94(10 SUPPL 1 PART 1): 92a, Nov 15, 1999

Interim results of a phase I/II radioimmunotherapy trial in relapsed/refractory non-Hodgkins lymphoma patients given 90Y-labeled anti-CD22 humanized monoclonal antibody, epratuzumab. Blood 98(11 Part 1): 611a, November 16, 2001

Radioimmunotherapy of refractory non-Hodgkins lymphoma with 131I-labeled chimeric 81C6 anti-tenascin monoclonal antibody Dosimetry study. Journal of Nuclear Medicine 43(5 Supplement): 313P, 2002